Всемирная Организация Здравоохранения и Международная организация по проблемам болезни Альцгеймера. Деменция: приоритет общественного здравоохраненияhttp://apps.who.int/iris/bitstream/10665/75263/14/9789244564455_rus.pdf?ua=1. Дата обращения- 30.08.2018 г.
Яхно Н.Н., Захаров В.В., Локшина А.Б., Коберская Н.Н., Мхитарян Э.А. Деменции: руководство для врачей / - 3-е изд. - М. : МЕД преcс-информ, 2011. - 272 с.
Selkoe D.J., Hardy J. The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Mol Med. 2016 Jun; 8(6):595-608. DOI: 10.15252/emmm.201606210.
Savva G.M., Wharton S.B., Ince P.G., Forster G., Matthews F.E., Brayne C. Medical Research Council Cognitive Function and Ageing Study: Age, neuropathology, and dementia. N Engl J Med. 2009; 360: 2302-2309. DOI:10.1056/NEJMoa0806142.
Zlokovic B.V. Neurovascular mechanisms of Alzheimer’s neurodegeneration. Trends Neurosci 2005; 28: 202-208. DOI: 10.1016/j.tins.2005.02.001
Wintermark M., Sesay M., Barbier E., Borbély K., Dillon W.P., Eastwood J.D. et al. Comparative overview of brain perfusion imaging techniques. J Neuroradiol 2005;32:294-314. DOI: 10.1161/01.STR.0000177884.72657.8b
Grade M., Hernandez Tamames J.A., Pizzini F.B., Achten E., Golay X., Smits M. A neuroradiologist’s guide to arterial spin labeling MRI in clinical practice. Neuroradiology 2015; 57:1181-1202.
Floyd T.F., Ratcliffe S.J., Wang J., Resch B., Detre J.A. Precision of the CASL-perfusion MRI technique for the measurement of cerebral blood flow in whole brain and vascular territories. J MagnReson Imaging. 2003; 18: 649-655.
Parkes L.M., Rashid W., Chard D.T., Tofts P.S. Normal cerebral perfusion measurements using arterial spin labeling: reproducibility, stability, and age and gender effects. Magn Reson Med. 2004; 51: 736-743.
Detre J.A., Leigh J.S., Williams D.S., Koretsky A.P. Perfusion imaging. Magnetic Resonance in Medicine. 1992;23:37-45.
Detre J.A., Rao H., Wang D.J., Chen Y.F., Wang Z.J. Applications of arterial spin labeled MRI in the brain. MagnReson Imaging. 2012 May; 35 (5): 1026-37.
Golay X, Hendrikse J, Lim T.C. Perfusion imaging using arterial spin labeling. Top MagnReson Imaging. 2004 Feb; 15(1):10-27.
Asllani I., Habeck C., Scarmeas N., Borogovac A., Brown T.R., Stern Y. Multivariate and univariate analysis of continuous arterial spin labeling perfusion MRI in Alzheimer’s disease. J. Cereb. Blood Flow Metab. 2008, 28, 725-736. DOI: 10.1038/sj.jcbfm.9600570
Mak H.K., Chan Q., Zhang Z., Petersen E.T., Qiu D., Zhang L., Yau K.K., Chu L.W., Golay X. Quantitative assessment of cerebral hemodynamic parameters by QUASAR arterial spin labeling in Alzheimer’s disease and cognitively normal Elderly adults at 3-tesla. J Alzheimers Dis. 2012;31(1):33-44. doi: 10.3233/JAD-2012-111877.
Okonkwo O.C., Xu G., Oh J.M., Dowling N.M., Carlsson C.M., Gallagher C.L. et. al. Cerebral blood flow is diminished in asymptomatic middle-aged adults with maternal history of Alzheimer’s disease Cereb Cortex. 2014 Apr;24(4):978-88. doi: 10.1093/cercor/bhs381.
Yoshiura T., Hiwatashi A., Yamashita K., Ohyagi Y., Monji A., Takayama Y., Nagao E., Kamano H., Noguchi T., Honda H. Simultaneous measurement of arterial transit time, arterial blood volume, and cerebral blood flow using arterial spin-labeling in patients with Alzheimer disease. AJNR Am. J. Neuroradiol. 2009; 30: 1388-1393.
Binnewijzend M.A., Kuijer J.P., Benedictus M.R., van der Flier W.M., Wink A.M., Wattjes M.P., van Berckel B.N., Scheltens P., Barkhof F. Cerebral blood flow measured with 3D pseudocontinuous arterial spin-labeling MR imaging in Alzheimer disease and mild cognitive impairment: a marker for disease severity. Radiology. 2013; 267: 221-230.
Musiek E.S., Chen Y., Korczykowski M., Saboury B., Martinez P.M., Reddin J.S., Alavi A., Kimberg D.Y., Wolk D.A., Julin P., Newberg A.B., Arnold S.E., Detre J.A. Direct comparison of fluorodeoxyglucose positron emission tomography and arterial spin labeling magnetic resonance imaging in Alzheimer’s disease. Alzheimers Dement 2012; 8: 51-59.
Tosun D., Schuff N., Jagust W., Weiner M.W. Discriminative power of arterial spin labeling magnetic resonance imaging and 18F-fluorodeoxyglucose positron emission tomography changes for amyloid-beta-positive subjects in the alzheimer’s disease continuum. Neurodegener. Dis. 2016; 16: 87-94.
Yoshiura T., Hiwatashi A., Noguchi T., Yamashita K., Ohyagi Y., Monji A., Nagao E., Kamano H., Togao O., Honda H. Arterial spin labelling at 3-T MR imaging for detection of individuals with Alzheimer’s disease. Eur. Radiol. 2009; 19: 2819-2825.
Benedictus M.R., Binnewijzend M.A., Kuijer J.P., Steenwijk M.D., et al. Brain volume and white matter hyperintensities as determinants of cerebral blood flow in Alzheimer’s disease. Neurobiol Aging. 2014 Dec; 35 (12): 2665-2670. doi: 10.1016/j.neurobiolaging.2014.06.001.
Zhang Q., Stafford R.B., Wang Z., Arnold S.E., Wolk D.A., Detre J.A. Microvascular perfusion based on arterial spin labeled perfusion MRI as a measure of vascular risk in Alzheimer’s disease J. Alzheimers Dis. 2012; 32: 677-687.
Wahlund L.O., Barkhof F., Fazekas F., Bronge L., Augustin M., Sjögren M. et al. A New Rating Scale for Age-Related White Matter Changes Applicable to MRI and CT on behalf of the European Task Force on Age-Related White Matter Changes. Stroke. 2001;32:1318.
Alba Sierra-Marcos Regional Cerebral Blood Flow in Mild Cognitive Impairment and Alzheimer’s Disease Measured with Arterial Spin Labeling Magnetic Resonance Imaging. International Journal of Alzheimer’s Disease 2017; Article ID: 5479597. DOI: [10.1155/2017/5479597]
Schuff N., Matsumoto S., Kmiecik J., Studholme C., Du A., Ezekiel F. et al. Cerebral blood flow in ischemic vascular dementia and Alzheimer’s disease, measured by arterial spin-labeling magnetic resonance imaging. Alzheimers Dement. 2009; Nov; 5 (6): 454-62. doi: 10.1016/j.jalz.2009.04.1233.
Kimura N., Nakama H., Nakamura K., Aso Y., Kumamoto T. Effect of white matter lesions on brain perfusion in Alzheimer’s disease. Dement Geriatr Cogn Disord. 2012; 34 (3-4): 256-61. doi: 10.1159/000345184.
Shi Y., Thrippleton M.J., Makin S.D., Marshall I., Geerlings M.I., de Craen A.J.M., van Buchem M.A., Wardlaw J.M. Cerebral blood flow in small vessel disease: A systematic review and meta-analysis. J Cereb Blood Flow Metab. 2016 Oct; 36 (10):1653-1667. DOI: 10.1177/0271678X16662891
van der Flier W.M., Middelkoop H.A., Weverling-Rijnsburger A.W., Admiraal-Behloul F., Spilt A., Bollen E.L. et al. Interaction of medial temporal lobe atrophy and white matter hyperintensities in AD. Neurology. 2004 May 25; 62 (10): 1862-4.
Brickman A.M., Honig L.S., Scarmeas N., Tatarina O., Sanders L., Albert M.S., Brandt J. et al. Measuring cerebral atrophy and white matter hyperintensity burden to predict the rate of cognitive decline in Alzheimer disease. Arch Neurol. 2008 Sep; 65 (9):1202-8. doi: 10.1001/archneur.65.9.1202.
Austin B.P., Nair V.A., Meier T.B., Xu G., Rowley H.A., Carlsson C.M. Effects of hypoperfusion in Alzheimer’s disease. J Alzheimers Dis. 2011; 26 Suppl 3: 123-33. doi: 10.3233/JAD-2011-0010.
Chen Y., Wan H.I., O’Reardon J.P., Wang D.J., Wang Z., Korczykowski M., Detre J.A. Quantification of cerebral blood flow as biomarker of drug effect: arterial spin labeling phMRI after a single dose of oral citalopram. Clin Pharmacol Ther. 2011 Feb; 89 (2): 251-8. doi: 10.1038/clpt.2010.296.